Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: TP2 Clear all
Withdrawn No phase listed Observational

Evaluation of Sleep Quality in Head and Neck Cancer Patients Throughout Treatment Course

NCT05108233
View directory record Official record
Conditions
Malignant Head and Neck Neoplasm
Interventions
Survey Administration
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 24, 2026, 2:55 PM EDT
Completed Phase 1Phase 2 Interventional Results available

INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma

NCT03502785
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
INO-5401, INO-9012, Atezolizumab, CELLECTRA® 2000
Biological · Drug · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
11
States / cities
Phoenix, Arizona • Tampa, Florida • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 24, 2026, 2:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of Different Oral Rehydration Solutions on the Hydration Status of Healthy Males

NCT05428774
View directory record Official record
Conditions
Fluid Retention, Beverage Hydration Index, Hydration Status
Interventions
Test product 1, Test product 2, Placebo
Other
Lead sponsor
Liquid I.V.
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Oct 24, 2026, 2:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate the Effects of Itraconazole and Carbamazepine on the Pharmacokinetics of Emraclidine and of Emraclidine on the Pharmacokinetics of Metformin in Healthy Adult Participants

NCT05965219
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Emraclidine, Itraconazole, Carbamazepine, Metformin
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 24, 2026, 2:55 PM EDT
Completed Phase 1 Interventional

hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse

NCT02960594
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Pancreatic Cancer, Head and Neck Cancer, Ovarian Cancer, ColoRectal Cancer, Gastric Cancer, Esophageal Cancer, HepatoCellular Carcinoma
Interventions
INO-1400, INO-9012, INO-1401
Biological
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Detroit, Michigan • Rochester, Minnesota • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 24, 2026, 2:55 PM EDT
Terminated Phase 2 Interventional

DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1 in Chronic Lymphocytic Leukemia

NCT03265717
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
INVAC-1
Biological
Lead sponsor
Invectys
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Oct 24, 2026, 2:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers

NCT03441984
View directory record Official record
Conditions
HIV Infections
Interventions
Treatment A, Treatment B, Treatment C, Treatment D, Treatment E, Treatment F
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 24, 2026, 2:55 PM EDT
Active, not recruiting Phase 2 Interventional

Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

NCT06293365
View directory record Official record
Conditions
Sjögrens Disease, Systemic Lupus Erythematosus, Rheumatoid Arthritis
Interventions
VAY736 1ml PFS, VAY736 2 ml PFS, VAY736 2ml AI
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
17
States / cities
Anniston, Alabama • Fullerton, California • La Palma, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 24, 2026, 2:55 PM EDT
Completed Phase 2 Interventional Results available

PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus

NCT04300296
View directory record Official record
Conditions
Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris
Interventions
secukinumab 300 mg Q4W, secukinumab 300 mg Q2W, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
15
States / cities
Birmingham, Alabama • Thousand Oaks, California • Cromwell, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 24, 2026, 2:55 PM EDT
Completed Phase 2 Interventional Results available

Evaluate SAGE-547 in Participants With Essential Tremor

NCT02277106
View directory record Official record
Conditions
Essential Tremor
Interventions
SAGE-547, Placebo
Drug
Lead sponsor
Sage Therapeutics
Industry
Eligibility
35 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Bingham Farms, Michigan • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Oct 24, 2026, 2:55 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Clinical Study to Evaluate the Effects of Two Novel Hydration Beverage Formulas on Rehydration in Healthy Adults

NCT05428228
View directory record Official record
Conditions
Dehydration, Rehydration, Exercise Performance, Exercise Recovery, Cognitive Performance
Interventions
TP1, TP2, Placebo
Other
Lead sponsor
Liquid I.V.
Other
Eligibility
18 Years to 35 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Oct 24, 2026, 2:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Clinical Trial to Evaluate the Effects of Two Novel Hydration Beverage Formulas on Rehydration in Healthy Adults

NCT05428761
View directory record Official record
Conditions
Dehydration, Rehydration, Exercise Performance, Exercise Recovery, Fluid Balance, Cognitive Performance
Interventions
TP1, TP2, Placebo
Other
Lead sponsor
Liquid I.V.
Other
Eligibility
18 Years to 49 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Oct 24, 2026, 2:55 PM EDT
Completed Phase 2 Interventional

A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML)

NCT00510133
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
GRNVAC1
Biological
Lead sponsor
Asterias Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
6
States / cities
Atlanta, Georgia • Maywood, Illinois • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Oct 24, 2026, 2:55 PM EDT
Not listed Phase 2 Interventional

Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma

NCT03190824
View directory record Official record
Conditions
Melanoma Stage III, Melanoma Stage Iv
Interventions
OBP-301
Drug
Lead sponsor
Syneos Health
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 24, 2026, 2:55 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

NCT03491683
View directory record Official record
Conditions
Glioblastoma
Interventions
INO-5401, INO-9012, Cemiplimab, Radiation Therapy, Temozolomide
Biological · Radiation · Drug
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
21
States / cities
Duarte, California • Palo Alto, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 24, 2026, 2:55 PM EDT